Posted by Michael Wonder on 30 Jul 2025
Johnson & Johnson files with US FDA to include new evidence in Tremfya (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis
29 July 2025 - Submission is supported by 24 week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with Tremfya, the only dual acting IL-23 inhibitor.
Johnson & Johnson today announced the submission of a supplemental biologics license application to the US FDA seeking approval to include new evidence in the Tremfya (guselkumab) label for the inhibition of progression of structural damage in adults with active psoriatic arthritis.
